Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide - Centre de recherche Saint-Antoine - UMR S938 Accéder directement au contenu
Article Dans Une Revue Molecular Therapy - Nucleic Acids Année : 2016

Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide

Résumé

Our purpose was to develop a new pharmacological approach for the treatment of prostate cancer (PCa), the most common neoplasia in men. Recently, we developed siRNA against the fusion oncogene TMPRSS2-ERG found in 50% of patients and showed an antitumoral activity in animal model. Herein, we want to compare or combine the developed siRNA to flutamide (FLU), one of the gold-standard treatment of PCa. Therefore, concomitant or subsequent association of FLU to siRNA TMPRSS2-ERG was performed in VCaP cells and in SCID mice bearing xenografted VCaP tumors. ERG, androgen receptor, cleaved-caspase-3 as well as phase 1 and 2 drug-metabolizing enzymes were investigated within tumors. We observed similar results in terms of TMPRSS2-ERG knock-down and cell viability impairment for all distinct schedules of administration. The association of siRNA TMPRSS2-ERG-squalene nanoparticles with flutamide displayed similar tumor growth inhibition as mice treated with siRNA TMPRSS2-ERG-squalene nanoparticles alone and was paralleled with modification of expression of ERG, androgen receptor, and cleaved-caspase-3. Phase 1 and 2 enzymes were essentially affected by FLU and reverted when combined with squalenoylated siRNA. In conclusion, these results confirm the therapeutic effectiveness of squalenoyl siRNA nanomedicine for PCa based on siRNA TMPRSS2-ERG.
Fichier principal
Vignette du fichier
Urbinati_Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA could be an alternative treatment to flutamide.pdf (1.64 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-02329823 , version 1 (22-12-2020)

Identifiants

Citer

Giorgia Urbinati, Isabelle I. de Waziers, Mateja Slamiç, Tobias Foussigniere, Hafiz Ali, et al.. Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide. Molecular Therapy - Nucleic Acids, 2016, 5, pp.e301. ⟨10.1038/mtna.2016.16⟩. ⟨hal-02329823⟩
68 Consultations
25 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More